Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Čermák J[au]:

Search results

Items: 1 to 50 of 310

1.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

2.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

3.

ASXL1 gene alterations in patients with isolated 20q deletion.

Brezinova J, Sarova I, Svobodova K, Lhotska H, Ransdorfova S, Izakova S, Pavlistova L, Lizcova L, Skipalova K, Hodanova L, Markova J, Zemanova Z, Cermak J, Jonasova A, Michalova K.

Neoplasma. 2019 Mar 10;2019:627-630. doi: 10.4149/neo_2018_181010N754.

PMID:
30868899
4.

Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the XRCC2 Gene.

Valka J, Vesela J, Votavova H, Dostalova-Merkerova M, Urbanova Z, Jonasova A, Cermak J, Belickova M.

Oncol Res Treat. 2019;42(5):263-268. doi: 10.1159/000497209. Epub 2019 Mar 12.

PMID:
30861523
5.

Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes.

Merkerova MD, Remesova H, Krejcik Z, Loudova N, Hrustincova A, Szikszai K, Cermak J, Jonasova A, Belickova M.

Cells. 2018 Sep 14;7(9). pii: E138. doi: 10.3390/cells7090138.

6.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

7.

Granulocytopenia.

Čermák J.

Vnitr Lek. Summer 2018;64(5):520-525.

PMID:
30193521
8.

Autoimmune hemolytic anemia.

Čermák J, Písačka M.

Vnitr Lek. Summer 2018;64(5):514-519.

PMID:
30193520
9.

Paroxysmal nocturnal hemoglobinuria.

Čermák J.

Vnitr Lek. Summer 2018;64(5):508-513.

PMID:
30193519
10.

Aplastic anemia.

Čermák J.

Vnitr Lek. Summer 2018;64(5):501-507.

PMID:
30193518
11.

Hemoglobinopathies.

Indrák K, Divoká M, Pospíšilová D, Čermák J, Beličková M, Horváthová M, Divoký V.

Vnitr Lek. Summer 2018;64(5):476-487. Review.

PMID:
30193516
12.

Differential diagnosis of anemia.

Válka J, Čermák J.

Vnitr Lek. Summer 2018;64(5):468-475.

PMID:
30193515
13.

Evaluation of toxicological and teratogenic effects of carbosilane glucose glycodendrimers in zebrafish embryos and model rodent cell lines.

Liegertová M, Wrobel D, Herma R, Müllerová M, Šťastná LČ, Cuřínová P, Strašák T, Malý M, Čermák J, Smejkal J, Štofik M, Maly J.

Nanotoxicology. 2018 Oct;12(8):797-818. doi: 10.1080/17435390.2018.1475582. Epub 2018 Sep 5.

PMID:
30182770
14.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, Almeida AM, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members.

Blood Adv. 2018 Aug 28;2(16):2079-2089. doi: 10.1182/bloodadvances.2018020495.

15.

ESI-TOF mass spectrometry of cationic carbosilane dendrimers: A potent tool for characterization of structural defects.

Cuřínová P, Krupková A, Červenková Šťastná L, Müllerová M, Čermák J, Strašák T.

J Mass Spectrom. 2018 Oct;53(10):986-996. doi: 10.1002/jms.4269. Epub 2018 Aug 16.

PMID:
30019544
16.

MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.

Krejcik Z, Belickova M, Hrustincova A, Votavova H, Jonasova A, Cermak J, Dyr JE, Merkerova MD.

Cancer Biomark. 2018;22(1):101-110. doi: 10.3233/CBM-171029.

PMID:
29630523
17.

Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome.

Sullivan DA, Dana R, Sullivan RM, Krenzer KL, Sahin A, Arica B, Liu Y, Kam WR, Papas AS, Cermak JM.

Ophthalmic Res. 2018;59(4):193-205. doi: 10.1159/000487487. Epub 2018 Apr 6.

18.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.

Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.

19.

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.

Wierzbowska A, Wawrzyniak E, Pluta A, Robak T, Mazur GJ, Dmoszynska A, Cermak J, Oriol A, Lysak D, Arthur C, Doyle M, Xiu L, Ravandi F, Kantarjian HM.

Am J Hematol. 2018 May;93(5):E125-E127. doi: 10.1002/ajh.25062. Epub 2018 Feb 24. No abstract available.

20.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

21.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

22.

Alpha-2-HS-glycoprotein plasma level decrease correlates with age in patients with myelodysplastic syndromes.

Majek P, Pecankova K, Cermak J, Gasova Z, Prochazka B, Dyr JE.

Cancer Biomark. 2017 Dec 6;20(4):637-639. doi: 10.3233/CBM-170638.

PMID:
28869442
23.

Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.

Valka J, Vesela J, Votavova H, Dostalova-Merkerova M, Horakova Z, Campr V, Brezinova J, Zemanova Z, Jonasova A, Cermak J, Belickova M.

Eur J Haematol. 2017 Oct;99(4):323-331. doi: 10.1111/ejh.12920. Epub 2017 Jul 24.

PMID:
28681469
24.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.

Ann Hematol. 2017 Jul;96(7):1105-1112. doi: 10.1007/s00277-017-3009-7. Epub 2017 May 20.

25.

Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes.

Dostalova Merkerova M, Hrustincova A, Krejcik Z, Votavova H, Ratajova E, Cermak J, Belickova M.

Neoplasma. 2017;64(4):571-578. doi: 10.4149/neo_2017_411.

PMID:
28485163
26.

Clonal evolution in myelodysplastic syndromes.

da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, Stevens-Kroef MJ, Cermak J, Shiraishi Y, Chiba K, Tanaka H, Miyano S, de Witte T, Blijlevens NMA, Muus P, Huls G, van der Reijden BA, Ogawa S, Jansen JH.

Nat Commun. 2017 Apr 21;8:15099. doi: 10.1038/ncomms15099.

27.

Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes.

Hlaváčková A, Štikarová J, Pimková K, Chrastinová L, Májek P, Kotlín R, Čermák J, Suttnar J, Dyr JE.

Free Radic Biol Med. 2017 Jul;108:1-7. doi: 10.1016/j.freeradbiomed.2017.03.007. Epub 2017 Mar 12.

PMID:
28300669
28.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

J Intern Med. 2017 Mar;281(3):284-299. doi: 10.1111/joim.12579. Epub 2016 Dec 7.

29.

Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.

Monika Belickova M, Merkerova MD, Votavova H, Valka J, Vesela J, Pejsova B, Hajkova H, Klema J, Cermak J, Jonasova A.

Int J Hematol. 2016 Nov;104(5):566-573. Epub 2016 Jul 14.

PMID:
27416819
30.

Posttranslational Modifications of Red Blood Cell Ghost Proteins as "Signatures" for Distinguishing between Low- and High-Risk Myelodysplastic Syndrome Patients.

Pecankova K, Majek P, Cermak J, Dyr JE.

Turk J Haematol. 2017 Mar 1;34(1):111-113. doi: 10.4274/tjh.2016.0251. Epub 2016 Sep 9. No abstract available.

31.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. No abstract available.

32.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

33.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.

Belickova M, Vesela J, Jonasova A, Pejsova B, Votavova H, Merkerova MD, Zemanova Z, Brezinova J, Mikulenkova D, Lauermannova M, Valka J, Michalova K, Neuwirtova R, Cermak J.

Oncotarget. 2016 Jun 14;7(24):36266-36279. doi: 10.18632/oncotarget.9200.

34.

Molecular Characterization of β-Thalassemia in the Czech and Slovak Populations: Mediterranean, Asian and Unique Mutations.

Divoka M, Partschova M, Kucerova J, Mojzikova R, Cermak J, Pospisilova D, Fabryova V, Prochazkova D, Indrak K, Divoky V.

Hemoglobin. 2016 Jun;40(3):156-62. doi: 10.3109/03630269.2016.1152581. Epub 2016 Mar 9.

PMID:
26956563
35.

Disulfide subproteome alterations in the platelets of patients with myelodysplastic syndrome.

Pecankova K, Majek P, Cermak J, Dyr JE.

J BUON. 2015 Nov-Dec;20(6):1643-4. No abstract available.

36.

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K.

Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24.

PMID:
26851439
37.

Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.

Sarova I, Brezinova J, Zemanova Z, Ransdorfova S, Izakova S, Svobodova K, Pavlistova L, Berkova A, Cermak J, Jonasova A, Siskova M, Michalova K.

Leuk Res. 2016 Apr;43:51-7. doi: 10.1016/j.leukres.2016.01.001. Epub 2016 Jan 8.

PMID:
26821593
38.

[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].

Jonášová A, Červinek L, Bělohlávková P, Čermák J, Beličková M, Rohoň P, Černá O, Hochová I, Šišková M, Kačmářová K, Janoušová E.

Vnitr Lek. 2015 Dec;61(12):1028-33. Czech.

PMID:
26806497
39.

Biocompatible Size-Defined Dendrimer-Albumin Binding Protein Hybrid Materials as a Versatile Platform for Biomedical Applications.

Maly J, Stanek O, Frolik J, Maly M, Ennen F, Appelhans D, Semeradtova A, Wrobel D, Stofik M, Knapova T, Kuchar M, Stastna LC, Cermak J, Sebo P, Maly P.

Macromol Biosci. 2016 Apr;16(4):553-66. doi: 10.1002/mabi.201500332. Epub 2016 Jan 8.

PMID:
26748571
40.

Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups.

Majek P, Pecankova K, Cermak J, Dyr JE.

Biomed Res Int. 2015;2015:209745. doi: 10.1155/2015/209745. Epub 2015 Sep 13.

41.

VATS lobectomy, history, indication, contraindication and general techniques.

Hytych V, Horazdovsky P, Pohnan R, Pracharova S, Taskova A, Konopa Z, Cernovska M, Demes R, Cermak J, Vasakova M, Benej R.

Bratisl Lek Listy. 2015;116(7):400-3.

PMID:
26286240
42.

Peripheral blood mononuclear cell proteome changes in patients with myelodysplastic syndrome.

Pecankova K, Majek P, Cermak J, Dyr JE.

Biomed Res Int. 2015;2015:872983. doi: 10.1155/2015/872983. Epub 2015 Apr 16.

43.

Retinol binding protein 4 plasma level in myelodysplastic syndrome subgroups.

Majek P, Pecankova K, Cermak J, Gasova Z, Dyr JE.

Int J Lab Hematol. 2015 Oct;37(5):e127-8. doi: 10.1111/ijlh.12377. Epub 2015 May 6. No abstract available.

PMID:
25945923
44.

BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.

Basak A, Hancarova M, Ulirsch JC, Balci TB, Trkova M, Pelisek M, Vlckova M, Muzikova K, Cermak J, Trka J, Dyment DA, Orkin SH, Daly MJ, Sedlacek Z, Sankaran VG.

J Clin Invest. 2015 Jun;125(6):2363-8. doi: 10.1172/JCI81163. Epub 2015 May 4.

45.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
46.

Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.

Krejčík Z, Beličková M, Hruštincová A, Kléma J, Zemanová Z, Michalová K, Čermák J, Jonášová A, Dostálová Merkerová M.

Cancer Genet. 2015 Apr;208(4):156-61. doi: 10.1016/j.cancergen.2015.03.003. Epub 2015 Mar 12.

PMID:
25883014
47.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
48.

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.

Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H.

J Blood Med. 2015 Jan 8;6:25-9. doi: 10.2147/JBM.S64067. eCollection 2015.

49.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

50.

Acetone-induced polymerization of 3-aminopropyltrimethoxysilane (APTMS) as revealed by NMR spectroscopy – revisited.

Schraml J, Korec S, Krump M, Čermák J.

Magn Reson Chem. 2015 Feb;53(2):154-9. doi: 10.1002/mrc.4171. Epub 2014 Oct 22. No abstract available.

PMID:
25335777

Supplemental Content

Loading ...
Support Center